Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies

BACKGROUND AND OBJECTIVE: Abiraterone acetate is approved for the treatment of metastatic castration-resistant prostate cancer. The originator abiraterone acetate (OAA) formulation is poorly absorbed and exhibits large pharmacokinetic variability in abiraterone exposure. Abiraterone acetate fine par...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldwater, Ronald, Hussaini, Azra, Bosch, Bill, Nemeth, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488144/
https://www.ncbi.nlm.nih.gov/pubmed/28425029
http://dx.doi.org/10.1007/s40262-017-0536-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488144/
https://www.ncbi.nlm.nih.gov/pubmed/28425029
http://dx.doi.org/10.1007/s40262-017-0536-2

Ejemplares similares